On 28 June Trimb Healthcare AB completed the acquisition of a portfolio of well-established European OTC products from Cilag GmbH International and Janssen Pharmaceutica NV (collectively, “J&J”
Trimb acquires a portfolio of skin care brands in northern Europe
Trimb Healthcare AB (“Trimb”) has entered into a definitive agreement with CCS Healthcare Nordic AB (“CCS”) to acquire their portfolio of skin care products in Sweden, Norway and the UK (“CCS Skincare Brands”). The portfolio includes several well-established and highly recognized brands, including CCS Swedish Formula, Indy Beauty1, Oliva, Bamse2, and exclusive rights to DAX and Antibac in the consumer sales channel in Sweden. The CCS Skincare Brands’ sales and marketing organization in Stockholm will transfer to Trimb as part of the transaction. The closing of the transaction is expected to occur in January 2019.
Magnus Nylén, CEO of Trimb said,
“the CCS Skincare Brands have strong strategic fit with Trimb and will significantly strengthen our position in Sweden. We see meaningful marketing synergies within our core categories of skin care and foot care. CCS has built a strong foothold for their products and it is with great pride that we welcome these well-known brands to Trimb.”
For more information, please contact:
Magnus Nylén, CEO Trimb
Phone: +46 70 514 84 94
Anders Larnholt, VP M&A Trimb
Phone: +46 76 677 64 95
You’ve been the CEO since June; tell us about it.
I assumed the position of CEO at Trimb in the middle of June, just as we completed the acquisition of Pevaryl and Fungoral from J&J.
Trimb Healthcare AB (“Trimb”) has acquired CCS Healthcare AB’s ("CCS") OTC drugs in the Nordic region.